Cancer UrologyPub Date : 2023-05-13DOI: 10.17650/1726-9776-2023-19-1-25-34
V. S. Chaykov, I. Dementyev, O. Karyakin, E. O. Shchukina, A. V. Troyanov, S. A. Ivanov, A. Kaprin
{"title":"Retroperitoneoscopic access in organ-preserving treatment of renal cell carcinoma","authors":"V. S. Chaykov, I. Dementyev, O. Karyakin, E. O. Shchukina, A. V. Troyanov, S. A. Ivanov, A. Kaprin","doi":"10.17650/1726-9776-2023-19-1-25-34","DOIUrl":"https://doi.org/10.17650/1726-9776-2023-19-1-25-34","url":null,"abstract":"Background. Renal cell carcinoma is one of the most common urologic cancers. Due to development of modern diagnostic methods, kidney tumors are often diagnosed at early stages (cT1a-T1b). The golden standard of treatment of localized renal cell carcinoma is tumor resection. In retroperitoneoscopic access, the time to artery access is decreased, the risk of intra- and postoperative complications is reduced. Retroperitoneal access is preferable for tumors located on the lateral or posterior kidney surface.Aim. To analyze the results of treatment of patients after retroperitoneoscopic kidney resection.Materials and methods. Between 2018 and 2021, at the A.F. Tsyb Medical Radiological Research Center - branch of the National Medical Research Radiological Center 47 retroperitoneoscopic kidney resections were performed (29 (61.7 %) in men, 18 (38.3 %) in women) due to stage cT1aN0M0 renal cell carcinoma. Retrospective analysis of demographic data, comorbid status, tumor characteristics, operative time, blood loss volume, frequency and severity of complications per the Clavien-Dindo classification was performed. Complexity of resection was evaluated using the R.E.N.A.L. scale.Results. Mean patient age was 63 (38-79) years, body mass index was 29.9 (22-39) kg/m2. Tumor of the left kidney was diagnosed in 24 (51.0 %) cases, of the right kidney - in 22 (46.8 %) cases, bilateral lesions - in 1 (2.2 %) case. Mean tumor size was 22.4 (11-39) mm. Resection had low complexity in 35 (74.5 %) cases, intermediate complexity in 12 (25.5 %) cases. Mean operative time was 156 (80-280) minutes, mean warm ischemia time was 19 (7-32) minutes, number of resections with zero ischemia was 15 (31.9 %), mean blood loss volume was 53 (10-300) mL, number of resections without renal parenchyma suturing was 10 (21.3 %). Mean hospitalization time after surgery was 5 days. Postoperative complications were observed in 4 (8.5 %) cases: bleeding (severity grade II per the Clavien-Dindo classification) in 1 (2.1 %) case, postoperative infectious complications (severity grade II) - in 2 (4.2 %) cases, subcutaneous hematoma (severity grade I) - in 1 (2.1 %) case.Conclusion. Retroperitoneoscopic access is effective and safe. This is confirmed by low frequency and severity of postoperative complications. This access allows to reduce hospitalization time and pain management medication which accelerates patient mobilization and recovery. Comparative analysis shows that retroperitoneoscopic kidney resection has the same effectiveness as laparoscopic resection.","PeriodicalId":216890,"journal":{"name":"Cancer Urology","volume":"63 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130644674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer UrologyPub Date : 2023-05-13DOI: 10.17650/1726-9776-2023-19-1-102-114
S. Popov, R. Guseynov, V. Khizha, A. N. Yazenok, I. Orlov, K. V. Sivak, V. V. Perepelitsa, N. S. Bunenkov, A. S. Ulitina
{"title":"Prostate cancer: current situation in Russia and Saint Petersburg according to medical statistical indicators","authors":"S. Popov, R. Guseynov, V. Khizha, A. N. Yazenok, I. Orlov, K. V. Sivak, V. V. Perepelitsa, N. S. Bunenkov, A. S. Ulitina","doi":"10.17650/1726-9776-2023-19-1-102-114","DOIUrl":"https://doi.org/10.17650/1726-9776-2023-19-1-102-114","url":null,"abstract":"Background. Prostate cancer is one of the most common malignant neoplasms in the male population worldwide with high morbidity and mortality rates.Aim. To study the main medial statistical indicators of prostate cancer in Saint Petersburg and other regions of the Russian Federation.Materials and methods. The epidemiological indicators of prostate cancer for 2012-2021 in the Russian Federation, individual federal districts and Saint Petersburg were analyzed.Results. The prevalence of malignant neoplasms of the prostate has increased in recent years. At the same time, the number of cases of early-stage disease diagnosis has increased, one-year mortality has decreased, and 5-year survival has increased, which indicates proper quality of oncological care for the population. In some federal districts, unstable or negative dynamics of indicators compared to the average Russian data are observed, which requires further analysis.Conclusion. Evaluation of statistical measures of morbidity and mortality from malignant neoplasms of the prostate gland can be used to improve diagnostic algorithms and therapeutic tactics for this pathology.","PeriodicalId":216890,"journal":{"name":"Cancer Urology","volume":"45 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114675141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer UrologyPub Date : 2023-05-13DOI: 10.17650/1726-9776-2023-19-1-71-75
G. S. Petrosyan, A. Keln
{"title":"Classification urine leakage from urethrovesical anastomosis after prostatectomy","authors":"G. S. Petrosyan, A. Keln","doi":"10.17650/1726-9776-2023-19-1-71-75","DOIUrl":"https://doi.org/10.17650/1726-9776-2023-19-1-71-75","url":null,"abstract":"Background. Urine leakage from urethrovesical anastomosis (UVA) is a frequent and significant complication after prostatectomy.Aim. To determine frequency urine leakage from the anastomosis after prostatectomy, evaluate diagnostic methods, develop classification and management guidelines for patients with this complication.Materials and methods. A retrospective analysis of 1426 patients who underwent prostatectomy was performed. Results. In total, 97 (6.8 %) patients developed UVA failure in the early postoperative period. The complication was diagnosed on the 7th day after prostatectomy using retrograde cystography. An original classification urine leakage from the anastomosis after prostatectomy was proposed using numbers (0, I, II, III) and letters (A, B, C). In 50 (3.4 %) patients, grade I (A, B, C) UVA failure was diagnosed; 38 (2.7 %) patients had grade II (A, B, C) UVA failure; 9 (0.6 %) patients had grade III (A, B) UVA failure. The developed classification allows to accurately determine the severity of UVA failure and apply the appropriate methods for its correction.Conclusion. Urine leakage from UVA is a serious problem in surgical treatment of prostate cancer. Currently, it is necessary to systematize the available data and introduce unified classification and algorithm for correcting this complication into clinical practice.","PeriodicalId":216890,"journal":{"name":"Cancer Urology","volume":"43 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128811574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer UrologyPub Date : 2023-05-13DOI: 10.17650/1726-9776-2023-19-1-17-24
I. B. Kravtsov, V. Solodky, A. Pavlov, A. Dzidzaria, S. Fastovets, I. V. Khoroshevskaya
{"title":"The role of obesity in patients with renal cell carcinoma","authors":"I. B. Kravtsov, V. Solodky, A. Pavlov, A. Dzidzaria, S. Fastovets, I. V. Khoroshevskaya","doi":"10.17650/1726-9776-2023-19-1-17-24","DOIUrl":"https://doi.org/10.17650/1726-9776-2023-19-1-17-24","url":null,"abstract":"Renal cell carcinoma is one of the most common malignant neoplasms of the genitourinary system. Along with smoking and hereditary syndromes associated with mutations in the Von Hippel-Lindau (VHL) gene, obesity is one of the main risk factors for the development of renal cell carcinoma. Emerging data indicate a causal relationship between obesity and development of renal cell carcinoma. In a large study within the framework of the Metabolic Syndrome and Cancer project, clinical data on blood pressure, body mass index, blood glucose, cholesterol and triglycerides were collected in 560,388 people. Individually, high glucose and triglyceride levels, as well as high body mass index and blood pressure, correlated with an increased risk of renal cell carcinoma in men, while only body mass index had a significant correlation in women.","PeriodicalId":216890,"journal":{"name":"Cancer Urology","volume":"9 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128218677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer UrologyPub Date : 2023-05-13DOI: 10.17650/1726-9776-2023-19-1-76-84
K. Makarova, Y. Gumenetskaya, V. Biryukov, T. A. Rodina, A. B. Galitsyna, E. O. Shchukina, O. Karyakin, S. A. Ivanov, A. Kaprin
{"title":"Combined radiotherapy and hormone therapy in unfavorable intermediate risk prostate cancer","authors":"K. Makarova, Y. Gumenetskaya, V. Biryukov, T. A. Rodina, A. B. Galitsyna, E. O. Shchukina, O. Karyakin, S. A. Ivanov, A. Kaprin","doi":"10.17650/1726-9776-2023-19-1-76-84","DOIUrl":"https://doi.org/10.17650/1726-9776-2023-19-1-76-84","url":null,"abstract":"Background. Currently, the group of intermediate risk prostate cancer (PC) includes 2 subgroups - favorable and unfavorable intermediate risk according to the National Comprehensive Cancer Network (NCCN) classification. The optimal scope of therapy is not defined for the unfavorable intermediate risk subgroup. In particular, the need for and duration of hormone therapy (HT) during combined radiotherapy (CRT) have not yet been determined.Aim. To perform a comparative analysis of the efficacy and toxicity of CRT in patients with unfavorable intermediate risk treated with and without HT.Materials and methods. Eighty-four (84) patients with unfavorable intermediate risk PC were treated with CRT at the clinic of the A.F. Tsyb Medical Radiological Research Center between May 2016 and December 2020. Patients were divided into two groups: external beam radiation therapy + brachytherapy (n = 40) and external beam radiation therapy + brachytherapy + HT (n = 44). Conformal external beam radiation therapy was delivered with conventional fractionation to a total dose of 44-46 Gy and the 192Ir high-dose rate brachytherapy was delivered with a single fraction of 15 Gy. Median duration of HT consisting of gonadotropin-releasing hormone agonist was 6 months. Median age was 65.2 years (range: 49-80 years). Median follow-up was 58.1 months (range: 18.6-83.7 months).Results. With a median follow-up of 4.8 years, progression-free survival was 95 % and 97.6 % in the external beam radiation therapy + brachytherapy group and external beam radiation therapy + brachytherapy + HT group, respectively (p = 0.578). The break between treatment stages of more than 28 days was associated with a statistically significant increase in the risk of PC recurrence (p = 0.007). Overall survival for the external beam radiation therapy + brachytherapy group versus external beam radiation therapy + brachytherapy + HT group was 97.5 and 93.2 % (p = 0.376), respectively.Late genitourinary toxicity was grade I in 8 (9.5 %) patients and grade II in 1 (1.2 %) patient. Urethral stricture developed in 3 (3.6 %) patients. Late gastrointestinal toxicity was grade I in 7 (8.3 %) patients and grade II in 1 (1.2 %) patient. There were no statistically significant differences in the incidence of late complications between groups with and without HT. There was a statistically significant (p = 0.049) effect of prostate volume on the incidence of late radiation proctitis.Conclusion. There were no statistically significant differences in progression-free survival and overall survival in patients with unfavorable intermediate risk PC who received external beam radiation therapy + brachytherapy with or without HT. The incidence and severity of adverse events were acceptable and allowed patients with PC to maintain high quality of life.","PeriodicalId":216890,"journal":{"name":"Cancer Urology","volume":"41 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133538477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer UrologyPub Date : 2023-05-13DOI: 10.17650/1726-9776-2023-19-1-85-101
А.И. Стукань, А.Ю. Горяинова, М.М. Григорян, В.Ф. Кутян, В.С. Жданов, Т.Ю. Семиглазова, Е.Н. Имянитов, A. I. Stukan, A. Goryainova, M. Grigoryan, V. F. Kutyan, V. S. Zhdanov, T. Semiglazova, E. Imyanitov
{"title":"Androgen receptor signaling mechanism in prostate cancer: resistance to antiandrogen therapy and association with DNA repair genes","authors":"А.И. Стукань, А.Ю. Горяинова, М.М. Григорян, В.Ф. Кутян, В.С. Жданов, Т.Ю. Семиглазова, Е.Н. Имянитов, A. I. Stukan, A. Goryainova, M. Grigoryan, V. F. Kutyan, V. S. Zhdanov, T. Semiglazova, E. Imyanitov","doi":"10.17650/1726-9776-2023-19-1-85-101","DOIUrl":"https://doi.org/10.17650/1726-9776-2023-19-1-85-101","url":null,"abstract":"Background. Metastatic castration-resistant prostate cancer remains a complex problem due to patients' previous treatments and limited selection of subsequent therapies. While 2nd generation antiandrogens are initially effective, resistance to them is not an exceptional event. Mechanisms depending on androgen receptor and independent of it have been described. A special focus is on mutations in DNA repair genes, particularly genes involved in homologous recombination repair (HRR) as a possible cause of somatic genetic abnormalities specifically in progressive metastatic disease. However, data on the effect of the HRR defect on the effectiveness of antiandrogen therapy for prostate cancer are very limited, which requires additional clinical studies.Aim. To evaluate the effect of clinical, morphological, molecular and genetic factors on the effectiveness of enzalutamide antiandrogen therapy in patients with prostate cancer and known mutations in DNA repair genes involved in HRR and mismatch repair.Materials and methods. The study was performed at the Clinical Oncological Dispensary No. 1 (Krasnodar). Retrospective analysis of clinical and morphological parameters of 54 patients with prostate cancer who received enzalutamide antiandrogen therapy and with known status of germ line and somatic mutations of HRR DNA repair genes (BRCA1, BRCA2, ATM, BARD, BRIP1, CDK12, CHEK1, CHEK2, PALB2, RAD51B, RAD51C, RAD54L, FANCL) and microsatellite instability in immunohistochemical determination of mismatch repair deficit was performed. Statistical analysis was performed using IBM SPSS Statistics v.22 software.Results and conclusion. In 17 of 54 patients, pathogenic germline and somatic mutations of HRR genes were detected: 7 mutations in BRCA2 gene, 4 - in CHEK2, 2 - in BRCA1, 2 - in CDK12, 1 - in BRIP1 and 1 - in ATM. It was shown that in the group of patients with metastatic castration-resistant prostate cancer, histological grade per the International Society of Urological Pathology (ISUP) G2 (total Gleason score 7 (3 + 4)) is significantly associated with the absence of HRR mutation, and grade G3 (total Gleason score 7 (4 + 3)) was associated with HRR mutations (р <0.05). Increase in prostate-specific antigen (PSA) level/biochemical progression 12-16 weeks after enzalutamide therapy start was significantly associated with metastatic castration-resistant prostate cancer without HRR mutations (р <0.05). In case of tumor response to enzalutamide therapy, decrease in PSA level did not depend on the age of disease onset, differentiation grade, primary advancement, previous docetaxel treatment, and presence of HRR mutation. Cox multivariate regression test showed that prescription of docetaxel before enzalutamide increased the risk of PSA-progression (hazard ratio (HR) 5.160; 95 % confidence interval (CI) 1.549-17.189; р = 0.008) and radiographic progression (HR 5.161; 95 % CI 1.550-17.187; р = 0.008). Progression risk decreased with increased level of PSA decreas","PeriodicalId":216890,"journal":{"name":"Cancer Urology","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128947967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer UrologyPub Date : 2023-05-13DOI: 10.17650/1726-9776-2023-19-1-115-128
E. Mamizhev, T. K. Kemryugov, B. Aslanov, D. V. Nekrasov, O. V. Lavrinovich, D. Rumyantseva, A. Nosov
{"title":"Preservation of fertility in patients with testicular germ cell tumors: oncological, legal, and religious aspects","authors":"E. Mamizhev, T. K. Kemryugov, B. Aslanov, D. V. Nekrasov, O. V. Lavrinovich, D. Rumyantseva, A. Nosov","doi":"10.17650/1726-9776-2023-19-1-115-128","DOIUrl":"https://doi.org/10.17650/1726-9776-2023-19-1-115-128","url":null,"abstract":"Survival rates for cancer patients continue to steadily increase due to improvement of effectiveness of current treatments. However, despite significant oncological results, one should not forget about the quality of life of this cohort of patients, in particular those who undergo gonadotoxic cancer therapy with development of premature ovarian failure in women and azoospermia in men. Preservation of fertility in both women and men with cancer is currently possible and should be integrated at all levels of cancer care. In this regard, the main purpose of this review is to consider the topic of fertility in men treated for cancer in the context of various aspects of human life.","PeriodicalId":216890,"journal":{"name":"Cancer Urology","volume":"40 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122345991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer UrologyPub Date : 2023-05-13DOI: 10.17650/1726-9776-2023-19-1-129-132
S. I. Aizat, M. Yusof, F. Lee, O. Fahmy, C. K. Lee, M. K. Khairul Asri, N. Muhammad Nasrulazam, V. K. Vikinesan, Y. Liyana Zayani, M. Yusuf, Y. Rashide, A. Othman
{"title":"Largest testicular tumour in South-East Asia: a case report","authors":"S. I. Aizat, M. Yusof, F. Lee, O. Fahmy, C. K. Lee, M. K. Khairul Asri, N. Muhammad Nasrulazam, V. K. Vikinesan, Y. Liyana Zayani, M. Yusuf, Y. Rashide, A. Othman","doi":"10.17650/1726-9776-2023-19-1-129-132","DOIUrl":"https://doi.org/10.17650/1726-9776-2023-19-1-129-132","url":null,"abstract":"We present the largest testicular tumour that first ever reported in Malaysia and we believed first reported in Southeast Asia. A 21 years old Malay gentleman presented to us with painless large scrotal swelling. After the initial workup and investigations were done and followed by a CT scan which yield a multiple paraaortic lymph nodes, the patient was scheduled listed in the earliest list for high ligation right orchidectomy with an inguinal approach. The patient seeks treatment at that point because he can't bear the embarrassment and fear of the treatment.","PeriodicalId":216890,"journal":{"name":"Cancer Urology","volume":"26 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125356138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer UrologyPub Date : 2023-05-12DOI: 10.17650/1726-9776-2023-19-1-160-168
A. Mylnikov, G. Maslyakova
{"title":"Epidemiological review of multiple primary malignant neoplasms of the prostate, kidney, and bladder","authors":"A. Mylnikov, G. Maslyakova","doi":"10.17650/1726-9776-2023-19-1-160-168","DOIUrl":"https://doi.org/10.17650/1726-9776-2023-19-1-160-168","url":null,"abstract":"Background. In recent years, an increase in the incidence of multiple primary malignancies has been observed. Multiple primary malignancies are an independent occurrence and development of two or more neoplasms of different histological origin in one patient.Aim. To evaluate epidemiological, clinical and morphological aspects of primary multiple malignant neoplasms of the prostate, kidney, and bladder.Materials and methods. Data analysis of the work report of the Saratov region oncological service in 2019, presented by the Regional Clinical Oncological Dispensary, patient case histories in the archive of the medical information system was performed.We performed a comparative analysis of the literature sources and data we obtained based to the following criteria: topographic anatomical combination of tumor locations, distribution of tumor combinations depending on time of occurrence (synchronous, metachronous), dynamics of urogenital multiple primary malignancies diagnosis in 2012-2019, distribution by gender and age, combination of stages of tumor process in both tumors, distribution by combination of histological types.Results. Between 2012 and 2019, 783 cases of multiple primary tumors with lesions in the urogenital system were identified. We studied 186 cases with a combination of two malignant neoplasms in the prostate, kidney, and bladder. Tumors developed synchronously in 36 % of patients, metachronously in 64 %. Mean patient age was 75 years. Half of the cases were in the group of localized stages - 90 (48.4 %), with the most common combination of TI-TII stages observed in 46 (24.7 %) cases. Combinations of acinar adenocarcinoma of the prostate with urothelial carcinoma of the bladder (34.7 %), clear cell renal carcinoma (27.8 %), papillary urothelial carcinoma of the bladder (12.5 %) were the most common according to histological diagnosis of primary multiple tumors of the urogenital system.Conclusion. Over the recent years we can observe a steady growth of diagnosable urogenital multiple primary malignancies. Morphological verification of the tumor and revelation of the most frequent histological types allows to assume the presence of the common mechanisms of development and the influence of tumor microenvironment on the growth of both tumors in a multiple primary malignancies pair.","PeriodicalId":216890,"journal":{"name":"Cancer Urology","volume":"85 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124956155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer UrologyPub Date : 2023-05-12DOI: 10.17650/1726-9776-2023-19-1-133-140
E. Slepov, R. Zukov, M. S. Serbaeva, A. Karapetyan, O. Kashaeva, A. Pavlenko, Y. Kozina
{"title":"Possibility of modification of peripheral blood neutrophils functional activity during chemoradiotherapy in patients with anorectal cancer","authors":"E. Slepov, R. Zukov, M. S. Serbaeva, A. Karapetyan, O. Kashaeva, A. Pavlenko, Y. Kozina","doi":"10.17650/1726-9776-2023-19-1-133-140","DOIUrl":"https://doi.org/10.17650/1726-9776-2023-19-1-133-140","url":null,"abstract":"Background. Ionizing radiation is an effective antitumor therapy, but it has a serious negative effect on the immune system requiring the use of radiation reaction prevention and reduction methods. Neutrophils are a sensitive element of the immune system both in interaction with tumor tissue and in response to radiation injury.Aim. To evaluate functional activity of peripheral blood neutrophils by chemiluminescent analysis in patients with anorectal cancer after radiotherapy.Materials and methods. The study included 80 patients with anorectal cancer. Patients received chemo- and radio-therapy with 3D conformal radiotherapy and radiation therapy under visual control, followed by the use of radioprotector and without it. Neutrophil activity determined by chemiluminescent analysis.Results. In patients with anorectal cancer found maximum spontaneous and induced chemiluminescence acceleration. The chemiluminescence activation index with luminol is lower in patients with anorectal cancer, and with lucigenin shows no differences with the control group. The low luminol chemiluminescence maximum intensity, as well as the decrease in the synthesis of reactive secondary oxygen species in enzymatic systems, is likely regulatory intracellular limitations consequence. After treatment, patients with radioprotector showed a decrease in the number of parameters with statistically significant differences with the control group. Undesirable phenomena associated with sodium deoxyribonucleate therapy not detected in anorectal cancer patients during radiotherapy and subsequent observation period.Conclusion. During treatment, differences in chemiluminescence parameters suggest that ionizing radiation affects them in patients with anorectal cancer receiving standard chemoradiotherapy. Use of chemoradiotherapy with a radioprotector leads to indirect restoration of cellular functional activity. This is confirmed by luminol-dependent chemiluminescence faster reaching its maximum and a decrease in the number of significant differences from the control group after the start of the drug treatment.","PeriodicalId":216890,"journal":{"name":"Cancer Urology","volume":"407 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132319924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}